Q/C Technologies, Inc.

Q/C Technologies, Inc. is a clinical-stage pharmaceutical company operating through Pharmaceuticals and Computing Technology segments. It develops Isomyosamine, a small molecule that regulates the immunometabolic system to treat autoimmune diseases such as sarcopenia, frailty, adverse effects of diabetes and obesity drugs, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic CBD analog for epilepsy, pain, and anxiety/depression, and is involved in quantum computing technology for cryptocurrency applications. Formerly TNF Pharmaceuticals, Inc., it changed its name to Q/C Technologies, Inc. in September 2025, was founded in 2014, and is headquartered in New York, New York.